Results 11 to 20 of about 12,797 (181)
Acta Crystallographica Section E, 2008 The conformation of the title compound [systematic name: N-benzyl-2-(2-nitroimidazol-1-yl)acetamide], C12H12N4O3, can be described in terms of the relative orientation of three planar fragments, the imidazol group (A), benzyl group (B), and the ...
Bruno Dacunha-Marinho +4 more
doaj +4 more sources
Amides from Porcelia ponderosa Roots Display Efficacy In Vitro Against Intracellular Amastigotes of Trypanosoma cruzi. [PDF]
Chem BiodiversAmides from Porcelia ponderosa display potent activity against amastigotes from Trypanosoma cruzi. ABSTRACT In the present work, the MeOH extract from roots of Porcelia ponderosa R.E. Fries (Annonaceae) was subjected to several chromatographic techniques to afford three chemically related amides: N‐trans‐p‐coumaroyltyramine (1), N‐trans ...
Dos Santos CHT +6 more
europepmc +2 more sources
PLoS Neglected Tropical Diseases, 2022 BackgroundApproximately 6 million people worldwide are affected by Chagas disease, with many in the chronic phase of the disease (CCD). It is crucial to evaluate the effectiveness of benznidazole for CCD treatment.Methods/principal findingsWe updated a ...
Clara Crespillo-Andújar +6 more
doaj +1 more source
PLoS Neglected Tropical Diseases, 2020 Approximately 300,000 persons in the United States (US) are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease, but less than 1% are estimated to have received antiparasitic treatment.
Kota Yoshioka +3 more
doaj +1 more source
IL-10/STAT3/SOCS3 Axis Is Involved in the Anti-inflammatory Effect of Benznidazole
Frontiers in Immunology, 2019 Anti-parasitic treatment for Chagas disease mainly relies on benznidazole, which is virtually the only drug available in the market. Besides its anti-parasitic effects, benznidazole has anti-inflammatory properties. In this work we studied the mechanisms
Ágata C. Cevey +4 more
doaj +1 more source
Intrinsic and Chemotherapeutic Stressors Modulate ABCC-Like Transport in Trypanosoma cruzi
Molecules, 2021 Trypanosoma cruzi is the etiologic agent for Chagas disease, which affects 6–7 million people worldwide. The biological diversity of the parasite reflects on inefficiency of benznidazole, which is a first choice chemotherapy, on chronic patients.
Kelli Monteiro da Costa +5 more
doaj +1 more source
Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières [PDF]
, 2009 BACKGROUND: Chagas disease (American trypanosomiasis) is a zoonotic or anthropozoonotic disease caused by the parasite Trypanosoma cruzi. Predominantly affecting populations in poor areas of Latin America, medical care for this neglected disease is often
Oliver Yun +35 more
core +2 more sources
International Journal of Infectious Diseases, 2019 There is little published data on benznidazole dosing, or levels in cerebrospinal fluid. In this report, we describe the clinical course of an immunosuppressed patient with Chagas central nervous system involvement.
M. Montero +14 more
doaj +1 more source
Frontiers in Parasitology, 2023 BackgroundEvaluating the effectiveness of Chagas disease treatment poses challenges due to the lack of biomarkers for disease progression and therapeutic response. In this study, we aimed to assess the clearance of Trypanosoma cruzi (T.
Carlos Henrique Valente Moreira +27 more
doaj +1 more source
Trypanocidal activity of genotoxic concentration of benznidazole on epimastigote forms of Trypanosoma cruzi = Atividade tripanocida da concentração genotóxica do benzonidazol em formas epimastigotas de Trypanosoma cruzi [PDF]
Acta Scientiarum. Health Sciences, 2012 The genotoxicity of benznidazole at a concentration of 75 µM, used in the treatment of Chagas’ disease, has been recently reported. The present study evaluated the inhibitory effect of benznidazole on the growth of epimastigote forms of T. cruzi I and II
Edilson Nobuyoshi Kaneshima +4 more
doaj +1 more source